The Analysis of Multinational Cost-Effectiveness Data for Reimbursement Decisions
- 1 December 2010
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 28 (12) , 1079-1096
Abstract
Evidence produced by multinational trial-based cost-effectiveness studies is often used to inform decisions concerning the adoption of new healthcare technologies. A key issue relating to the use of this type of evidence is the extent to which trial-wide economic results are applicable to every single country participating in the study. We consider what role cost-effectiveness analysis alongside multinational trials should have in assisting reimbursement decisions at jurisdiction and national levels. Using the proposed framework as a benchmark to evaluate their relative pros and cons, we then describe and review the statistical approaches used in the multinational trial-based costeffectiveness literature. The results of the review are used to define the desirable characteristics a statistical method for the analysis of data collected from different jurisdictions should have in order to be consistent with the proposed framework. It is argued that Bayesian hierarchical models that use both patient- and country-level information are the most appropriate tool to analyse multinational trial-based cost-effectiveness data and facilitate the between-country generalizability assessment of the study findings. The merits of each approach are discussed, highlighting problems and limitations, in order to identify areas of future research.Keywords
This publication has 69 references indexed in Scilit:
- Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical TrialsPharmacoEconomics, 2009
- Cost-Effectiveness Analysis Using Data from Multinational Trials: The Use of Bivariate Hierarchical ModelingMedical Decision Making, 2007
- Collecting unit cost data in multicentre studiesThe European Journal of Health Economics, 2005
- Conducting economic evaluations alongside multinational clinical trials: Toward a research consensusAmerican Heart Journal, 2005
- Comparing costing results in across country economic evaluations: the use of technology specific purchasing power paritiesHealth Economics, 2004
- Individual patient‐ versus group‐level data meta‐regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly headStatistics in Medicine, 2002
- Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trialRadiotherapy and Oncology, 1999
- Analysis of homogeneity of treatment effect in adaptive multicenter clinical trialsJournal of Biopharmaceutical Statistics, 1998
- Heart FailurePharmacoEconomics, 1996
- Comparing Cost-Effectiveness Across CountriesPharmacoEconomics, 1994